KAPA
Kairos PharmaยทAMEX
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About KAPA
Kairos Pharma, Ltd.
A small California-based biotechnology company focused on cancer
2355 Westwood Blvd., #139, Los Angeles CA 90064
--
Kairos Pharma, Ltd., was incorporated under the laws of the State of California on June 17, 2013 as NanoGB 13, Inc., and subsequently converted to a Delaware corporation on May 10, 2023 as Kairos Pharma, Ltd. The company is a clinical-stage biopharmaceutical company dedicated to the treatment of cancer patients, aiming to overcome key barriers in immunosuppression and drug resistance. These therapies include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer and glioblastoma.
Company Financials
EPS
KAPA has released its 2025 Q3 earnings. EPS was reported at -0.07, versus the expected -0.08, beating expectations. The chart below visualizes how KAPA has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
